Miglustat — a component of AT-GAA, an investigational therapy for late-onset Pompe disease (PD) — enhances the activity of the other component in AT-GAA, cipaglucosidase alfa, researchers report. These findings were presented at the 2021 MDA Virtual Clinical & Scientific Conference, in the poster “Enhancing Delivery…
Pombiliti + Opfolda
Recent Posts
- Our family’s experience with Pompe disease is just one of many
- Use of methotrexate may make Pompe treatment more effective, per study
- 5 years strong: Combo LOPD therapy preserves walking and lung function
- You’re not failing if you can’t remember every detail about your child
- Muscle damage begins before visible changes appear in LOPD